FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W104398217> ?p ?o ?g. }

• W104398217 endingPage "410" @default.
• W104398217 startingPage "403" @default.
• W104398217 abstract "The primary aim of the study was to determine the antiplatelet effects of prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after percutaneous coronary intervention (PCI) and, secondarily, their relation to cytochrome (CYP) 2C19*2 carriage. High on-treatment platelet reactivity after clopidogrel administration after PCI is linked to the loss-of-function CYP2C19*2 allele and accompanied by an increased risk of adverse events. We performed a prospective, randomized, single-blind, crossover study of platelet inhibition by prasugrel 10 mg/day versus high-dose 150 mg/day clopidogrel in 71 (of 210 screened; 33.8%) post-PCI patients with HTPR. Platelet function was assessed by the VerifyNow assay (Accumetrics, San Diego, California), and real-time polymerase chain reaction genotyping was performed for CYP2C19*2 carriage. The primary endpoint of platelet reactivity (measured in platelet reactivity units) at the end of the 2 treatment periods was lower after prasugrel compared with clopidogrel (least-squares estimates 129.4, 95% confidence interval [CI]: 111.1 to 147.7 versus 201.7, 95% CI: 183.2 to 220.2; p < 0.001). The least-squares mean difference between the 2 treatments was −122.9 (95% CI: −166.7 to −79.2, p < 0.001), and −47.5 (95% CI: −79.5 to −15.4, p = 0.004), in carriers and noncarriers of at least 1 mutant allele, respectively. The HTPR rates were lower for prasugrel than for clopidogrel, in all patients (7.5% vs. 35.8%, p < 0.001), in carriers (5.3% vs. 47.4%, p = 0.007), and in noncarriers (8.8% vs. 29.4%, p = 0.005), respectively. In patients with HTPR after PCI, prasugrel is more effective compared with high clopidogrel in reducing platelet reactivity, particularly in CYP2C19*2 carriers. Genotyping guidance might be helpful only in case an increased clopidogrel maintenance dose is considered. (Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI); NCT01109784)" @default.
• W104398217 created "2016-06-24" @default.
• W104398217 creator A5005503597 @default.
• W104398217 creator A5015256804 @default.
• W104398217 creator A5016879313 @default.
• W104398217 creator A5042428811 @default.
• W104398217 creator A5066433642 @default.
• W104398217 creator A5085972858 @default.
• W104398217 creator A5088021132 @default.
• W104398217 creator A5088583326 @default.
• W104398217 date "2011-04-01" @default.
• W104398217 modified "2023-10-18" @default.
• W104398217 title "Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel" @default.
• W104398217 cites W119348236 @default.
• W104398217 cites W1756335821 @default.
• W104398217 cites W1956282284 @default.
• W104398217 cites W1964551540 @default.
• W104398217 cites W1968677865 @default.
• W104398217 cites W1974655135 @default.
• W104398217 cites W1985059672 @default.
• W104398217 cites W2005714426 @default.
• W104398217 cites W2021241943 @default.
• W104398217 cites W2047147079 @default.
• W104398217 cites W2048708470 @default.
• W104398217 cites W2057681387 @default.
• W104398217 cites W205995199 @default.
• W104398217 cites W2081548185 @default.
• W104398217 cites W2082149672 @default.
• W104398217 cites W2090989590 @default.
• W104398217 cites W2104595603 @default.
• W104398217 cites W2106146046 @default.
• W104398217 cites W2128228188 @default.
• W104398217 cites W2135575592 @default.
• W104398217 cites W2140319544 @default.
• W104398217 cites W2140776066 @default.
• W104398217 cites W2147746835 @default.
• W104398217 cites W2149465085 @default.
• W104398217 cites W2152823642 @default.
• W104398217 cites W2154940301 @default.
• W104398217 cites W2164386459 @default.
• W104398217 cites W2165620610 @default.
• W104398217 cites W2165637474 @default.
• W104398217 cites W2166650056 @default.
• W104398217 cites W2169387542 @default.
• W104398217 cites W30991610 @default.
• W104398217 cites W67811773 @default.
• W104398217 doi "https://doi.org/10.1016/j.jcin.2010.12.011" @default.
• W104398217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21511219" @default.
• W104398217 hasPublicationYear "2011" @default.
• W104398217 type Work @default.
• W104398217 sameAs 104398217 @default.
• W104398217 citedByCount "111" @default.
• W104398217 countsByYear W1043982172012 @default.
• W104398217 countsByYear W1043982172013 @default.
• W104398217 countsByYear W1043982172014 @default.
• W104398217 countsByYear W1043982172015 @default.
• W104398217 countsByYear W1043982172016 @default.
• W104398217 countsByYear W1043982172017 @default.
• W104398217 countsByYear W1043982172018 @default.
• W104398217 countsByYear W1043982172019 @default.
• W104398217 countsByYear W1043982172020 @default.
• W104398217 countsByYear W1043982172021 @default.
• W104398217 countsByYear W1043982172022 @default.
• W104398217 countsByYear W1043982172023 @default.
• W104398217 crossrefType "journal-article" @default.
• W104398217 hasAuthorship W104398217A5005503597 @default.
• W104398217 hasAuthorship W104398217A5015256804 @default.
• W104398217 hasAuthorship W104398217A5016879313 @default.
• W104398217 hasAuthorship W104398217A5042428811 @default.
• W104398217 hasAuthorship W104398217A5066433642 @default.
• W104398217 hasAuthorship W104398217A5085972858 @default.
• W104398217 hasAuthorship W104398217A5088021132 @default.
• W104398217 hasAuthorship W104398217A5088583326 @default.
• W104398217 hasBestOaLocation W1043982171 @default.
• W104398217 hasConcept C126322002 @default.
• W104398217 hasConcept C140840227 @default.
• W104398217 hasConcept C164705383 @default.
• W104398217 hasConcept C2777028646 @default.
• W104398217 hasConcept C2777628954 @default.
• W104398217 hasConcept C2777849778 @default.
• W104398217 hasConcept C2778905298 @default.
• W104398217 hasConcept C2780400711 @default.
• W104398217 hasConcept C35294091 @default.
• W104398217 hasConcept C45393284 @default.
• W104398217 hasConcept C49059817 @default.
• W104398217 hasConcept C500558357 @default.
• W104398217 hasConcept C526171541 @default.
• W104398217 hasConcept C62231903 @default.
• W104398217 hasConcept C71924100 @default.
• W104398217 hasConcept C98274493 @default.
• W104398217 hasConceptScore W104398217C126322002 @default.
• W104398217 hasConceptScore W104398217C140840227 @default.
• W104398217 hasConceptScore W104398217C164705383 @default.
• W104398217 hasConceptScore W104398217C2777028646 @default.
• W104398217 hasConceptScore W104398217C2777628954 @default.
• W104398217 hasConceptScore W104398217C2777849778 @default.
• W104398217 hasConceptScore W104398217C2778905298 @default.
• W104398217 hasConceptScore W104398217C2780400711 @default.

• next